These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10595817)

  • 1. Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia.
    Gladstone DE; Bedi A; Miller CB; Noga SJ; Griffin CA; Piantadosi S; Cagnoni PJ; Brodsky RA; Smith BD; Douglas TT; Shpall EJ; Jones RJ
    Biol Blood Marrow Transplant; 1999; 5(6):394-9. PubMed ID: 10595817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.
    Hájek R; Zácková D; Büchler T; Penka M; Krahulcová E; Korístek Z; Vinklárková J; Adler J; Janovská E; Indrák K; Faber E; Doubek M; Klabusay M; Oltová A; Kuglík P; Bourková L; Dusek L; Mareschová I; Mayer J; Vorlícek J
    Med Oncol; 2003; 20(1):69-76. PubMed ID: 12665687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
    Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
    Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
    Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
    Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML.
    McGlave P; Bhatia R; Verfaillie C
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S65-6. PubMed ID: 8769706
    [No Abstract]   [Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
    Gopcsa L; Barta A; Banyai A; Foldi J; Kalasz L; Pajor L; Gidali J; Regeczy N; Paloczi K
    Acta Haematol; 2001; 106(3):100-5. PubMed ID: 11713374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
    Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C
    Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of chronic myeloid leukemia and its relevance to autologous bone marrow transplantation.
    Jones RJ; Bedi A
    Curr Opin Oncol; 1994 Mar; 6(2):122-6. PubMed ID: 8011689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
    Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
    Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
    de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
    Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.
    Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL
    Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
    Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
    Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
    Jabro G; Koc Y; Boyle T; Schenkein DP; Ravalese J; Wazer D; Miller KB
    Biol Blood Marrow Transplant; 1999; 5(3):173-9. PubMed ID: 10392963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.